Albumin–Bilirubin Grade as a Valuable Predictor of Recurrence and Prognosis in Patients with Hepatocellular Carcinoma Following Radiofrequency Ablation
Cancers · 13.12.2024 · 16 (24) · 4167
DOI: 10.3390/cancers16244167 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 13.12.2024. Verfasst von Chang Hun Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Jeonbuk National University Medical School and Research Institute of Clinical Medicine of Jeonbuk National Universit…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jeonbuk National University, Jeonbuk National University Hospital.
Abstract (Originalsprache)
Background/Objectives: Radiofrequency ablation (RFA) is an important local treatment for hepatocellular carcinoma (HCC). This study aimed to evaluate the characteristics of tumor recurrence after RFA and analyze predictors of tumor recurrence and survival in patients with HCC.
Methods
We retrospectively reviewed data from treatment-naïve patients with HCC who underwent RFA for HCC treatment between 2008 and 2017 at four tertiary hospitals in South Korea.
Results
A total of 636 patients with HCC treated with RFA were enrolled in the study. The mean age was 66.3 ± 10.4 years, with 75.0% of patients being male. Most patients (96.7%) had underlying liver cirrhosis, and viral hepatitis (types B and C) accounted for most cases. The average maximum tumor size was 2.2 ± 0.9 cm, with 84.3% of tumors being single lesions. During the follow-up period, 331 patients experienced recurrence, with 95.5% of cases being intrahepatic and one-fifth occurring at the RFA site. Most patients underwent RFA or transarterial chemoembolization as subsequent therapy for recurrence. Multivariate analysis revealed that age, the albumin–bilirubin (ALBI) grade, and Child–Pugh class B status were independent factors associated with tumor recurrence. Only the ALBI grade was significantly associated with mortality. Additionally, the ALBI grade differentiated between recurrence-free survival and overall survival in the Kaplan–Meier survival curve.
Conclusions
The ALBI grade was independently associated with tumor recurrence and prognosis in patients with HCC following RFA. This grading system can help clinicians identify high-risk patients, optimize treatment strategies, and enhance patient care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Jeonbuk National University Medical School and Research Institute of Clinical Medicine of Jeonbuk National University Hospital-Jeonbuk National University Medical School, Jeonju 54907, R…
- Division of Gastroenterology, Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun 58128, Republic of Korea.
- Department of Internal Medicine, Wonkwang University College of Medicine, Iksan 54538, Republic of Korea.
- Division of Gastroenterology, Department of Internal Medicine, Chonnam National University Medical School, Gwangju 61469, Republic of Korea.
ORCID-Profile: Jae Hyun Yoon
Förderung
- Jeonbuk National University
- Jeonbuk National University Hospital
Zitieren
APA
Lee, C. H., You, G. R., Jo, H. G., Jun, C. H., Cho, E. Y., Kim, I. H., Choi, S. K., & Yoon, J. H. (2024). Albumin–Bilirubin Grade as a Valuable Predictor of Recurrence and Prognosis in Patients with Hepatocellular Carcinoma Following Radiofrequency Ablation. Cancers, 16(24), 4167. https://doi.org/10.3390/cancers16244167
Vancouver
Lee CH, You GR, Jo HG, Jun CH, Cho EY, Kim IH, et al. Albumin–Bilirubin Grade as a Valuable Predictor of Recurrence and Prognosis in Patients with Hepatocellular Carcinoma Following Radiofrequency Ablation. Cancers. 2024;16(24):4167. doi:10.3390/cancers16244167
BibTeX
@article{Lee2024,
author = {Lee, Chang Hun and You, Ga Ram and Jo, Hoon Gil and Jun, Chung Hwan and Cho, Eun Young and Kim, In Hee and Choi, Sung Kyu and Yoon, Jae Hyun},
title = {Albumin–Bilirubin Grade as a Valuable Predictor of Recurrence and Prognosis in Patients with Hepatocellular Carcinoma Following Radiofrequency Ablation},
journal = {Cancers},
year = {2024},
volume = {16},
number = {24},
pages = {4167},
doi = {10.3390/cancers16244167}
}
EUVIMED